Overview
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single-ascending and multiple-ascending doses of ALZ002 DS.
Eligibility
Inclusion Criteria:
- Healthy male and/or non-childbearing potential female subjects, non-smoker (no use of tobacco or nicotine products within 3 months prior to screening), 18 and 55 years of age at screening.
- Body mass index > 18.5 and < 30.0 kg/m2, and body weight 50.0 kg for males and 45.0 kg for females at screening visit.
- Capable of consent.
Exclusion Criteria:
- Any clinically significant abnormality or abnormal laboratory test results
- Positive urine drug screen, alcohol breath test, or urine cotinine test
- History of significant allergic reactions to any drug.
- Participation in a clinical research study involving the administration of an investigational or marketed drug or device
- History of clinically significant opportunistic infection
- Presence of fever (body temperature > 38C)